Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 2/3 1

Status

Completed 22Unknown 15Terminated 10Recruiting 7Not yet recruiting 3Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Lymphoma, Extranodal NK-T-Cell 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1

Interventions

Carboplatin 75Cisplatin 73Bevacizumab 64Radiotherapy 57Drug Therapy 56Capecitabine 56tislelizumab 54Oxaliplatin 54Gemcitabine 46toripalimab 45Paclitaxel 45Specimen Handling 43sintilimab 39pembrolizumab 39anlotinib 38Cyclophosphamide 33130-nm albumin-bound paclitaxel 32Magnetic Resonance Spectroscopy 27Injections 27camrelizumab 26Pemetrexed 26Surgical Procedures, Operative 25lenvatinib 23Docetaxel 23Biopsy 23apatinib 22Etoposide 22Immune Checkpoint Inhibitors 21S 1 (combination) 20Fluorouracil 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × pegaspargase × Clear all
NCT07554482 2026-04-28

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Beijing Tongren Hospital

Phase 2 Not yet recruiting
34 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT07457177 2026-03-09

Phaes â…¡ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL

Beijing Tongren Hospital

Phase 2 Not yet recruiting
40 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT07227584 2025-11-12

ALL Backbone in AYAs

Dana-Farber Cancer Institute

Phase 2 Not yet recruiting
67 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡